Hasten Biopharmaceutical Co., Ltd.

📢📢 🌞 🌞 We are pleased to announce that Azilsartan Medoxomil Potassium Tablets (Edarbi®), a potent antihypertensive drug of the angiotensin receptor antagonist (ARB) class for the treatment of essential hypertension in adults has gained contract renewal to be included in the updated National Reimbursement Drug List(NRDL), which will be effective on Jan. 1st of 2025. #Edarbi #ARB #hypertension #NRDL #innovation

On November 16th, 2024, Hasten Biopharmaceutical Co., Ltd. announced that the first subject was enrolled and dosed in the Phase III clinical trial of the new third-generation PCSK9 inhibitor, Lerodalcibep (hereinafter referred to as #HST101), which is jointly developed by Hasten and LIB Therapeutics. This marks a significant new milestone in Hasten's research and development journey, following the obtaining of clinical trial approval by NMPA earlier this year.   This study is a randomized, double-blind, placebo-controlled phase III clinical trial (CTR20242095/NCT06568471) aimed at evaluating the efficacy and safety of HST101 in Chinese patients with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). The study is led by Professor Huo Yong from Peking University First Hospital and is planned to be conducted at a total of 35 research centers across the country.   Prof. Shen Xiao, CMO of Hasten, said: "Following the positive results of the Phase III clinical trials announced by LIB at #EAS conference this year, Hasten has made every effort to actively promote its clinical development process in China. On September 18, the first patient in the phase I clinical trial of HST101 was enrolled and dosed successfully. We are very looking forward to witnessing the same excellent performance of the phase I and phase III clinical trials among Chinese patients, so as to providing new treatment options with more clinical value for doctors and patients, and helping more hyperlipidemia patients achieve LDL-C target as soon as possible." #LDL-C #PCSK9 #HST101 #Clinicaltrials #firstinjectionpatient

On November 16th, 2024, Hasten Biopharmaceutical Co., Ltd. announced that the first subject was enrolled and dosed in the Phase III clinical trial of the new third-generation PCSK9 inhibitor, Lerodalcibep (hereinafter referred to as #HST101), which is jointly developed by Hasten and LIB Therapeutics. This marks a significant new milestone in Hasten's research and development journey, following the obtaining of clinical trial approval by NMPA earlier this year.   This study is a randomized, double-blind, placebo-controlled phase III clinical trial (CTR20242095/NCT06568471) aimed at evaluating the efficacy and safety of HST101 in Chinese patients with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). The study is led by Professor Huo Yong from Peking University First Hospital and is planned to be conducted at a total of 35 research centers across the country.   Prof. Shen Xiao, CMO of Hasten, said: "Following the positive results of the Phase III clinical trials announced by LIB at #EAS conference this year, Hasten has made every effort to actively promote its clinical development process in China. On September 18, the first patient in the phase I clinical trial of HST101 was enrolled and dosed successfully. We are very looking forward to witnessing the same excellent performance of the phase I and phase III clinical trials among Chinese patients, so as to providing new treatment options with more clinical value for doctors and patients, and helping more hyperlipidemia patients achieve LDL-C target as soon as possible." #LDL-C #PCSK9 #HST101 #Clinicaltrials #firstinjectionpatient

On 16th, October 2024, Hasten Biopharmaceutical Co., Ltd. (hereinafter as Hasten) announced that a new network META article of azilsartan medoxomil (AZL-M) titled "A systematic literature review and network meta-analysis of azilsartan medoxomil compared to other anti-hypertensives efficacy in lowering blood pressure amongst mild to moderate hypertensive patients" had been published in the internationally renowned journal Advances in Therapy. According to the conclusion of this network META, AZL-M at 40mg and 80mg shows favorable efficacy compared to other anti-hypertensives, and the 80mg dosage seemed to be most efficacious of all the included treatments in reducing both office systolic and diastolic BP in patients with mild to moderate hypertension. The publication of the results of this META indicates the international peer-review’s recognition of the quality of this data analyzed. Prof. Shen Xiao, Chief Medical Officer of Hasten, stated that as a meta-analysis covering professional literature from the past 24 years, the META provides an adequate data support for assessing the efficacy of azilsartan medoxomil compared to other commonly used first-line antihypertensive drugs. The results of this network META indicate that azilsartan medoxomil, as an effective antihypertensive treatment for patients with mild to moderate hypertension, will offer a new and more effective option for the treatment of a greater number of hypertensive patients. #networkmetaanalysis #advancesintherapy #healthcare #hypertension #azilsartanmedoxomil

On Sept. 24, 2024, Hasten Biopharmaceutical Co., Ltd. and China Resources Pharmaceutical Commercial Group (Shanghai) Co., Ltd. signed a strategic agreement to deepen the comprehensive collaboration on further increasing branded drugs’ accessibility to Chinese patients.   Senior leadership team from Hasten, formed by Mr. Summer XIA Shaofei(CEO of Hasten), Mr. 顾羽亮(EVP), Mr. Hanson Zheng(SVP), Mr. Jun Cheng(VP and Head of Finance), etc., was invited to pay a visit to China Resources Office in Shenzhen. Mr. Junyu Guo(Member of the Party Committee and Deputy General Manager of China Resources), Mr. Tao Lang(Member of the Party Committee and Deputy General Manager), Mr. Jiajun Yu(Vice General Manager of CR Pharma Commercial Shanghai Region), Mr. Shengkun Kang(International Business and National Distribution Manager) received Hasten team and witnessed the conclusion of the strategic cooperation.   Summer XIA Shaofei, CEO of Hasten, said, “Hasten and China Resources (Shanghai) had built a trustable relationship since both parties signed the first contract on the 2023 CIIE. Today's reunion is a demonstration for the deep cooperation and high level of trust between both sides while pursuing common development. This is not only a complement in business, but also a fit in value and vision. Through this strategic cooperation, we will further integrate the strengths of both sides, jointly promote innovation and development in the field of healthcare, and benefit a wider range of patients.   Mr. Kevin Gu(顾羽亮), Executive Vice President of Hasten, said: “The prior innovative strategic cooperation between Hasten and China Resources (Shanghai) has achieved fruitful results in the past. This deep strategic cooperation will enable both sides to achieve comprehensive cooperation in omni-channel agent, extensive market cultivation and third-party logistics distribution in the fields of chronic diseases and critical illnesses. Through the efforts of both parties, we will benefit more patients and create significant social health value jointly. #strategicagreement #innovation #healthcare #cooperation

On September 6th, 2024, representatives from Celltrion visited the Shanghai Operations Management Center of Hasten Biopharmaceutical Co., Ltd.   To acknowledge the project members of both parties for their unremitting efforts for prior acquisition announced on June 28th and the following consistent transition, Hasten invited Celltrion delegation and project team members to jointly celebrate on the achievement of this milestone. During the small but innovative ceremony, Celltrion representative handed over to Hasten the “key of success” symbolizing that two companies’ shared vision of providing healthcare solutions for patients will be continued. Leaders from two parties also toasted for the milestone and win-win result.   Summer XIA Shaofei, CEO of Hasten, said, “it is our honor to be able to reunite with Celltrion in Hasten Shanghai Office. With this transaction, Hasten will fully accelerate the commercialization in the Pan-Asia region and further expand the international market, so as to bring more high-quality products and solutions to patients in the Asia-Pacific region and even around the world and create social value.”   CEO of Celltrion APAC, Ho Seung Shin said: “Congratulations to the Hasten team for successfully concluding this significant strategic cooperation and accelerating the commercialization of the Asia-Pacific region. It is believed that with Hasten's innovative business mode and strong commercial capabilities, the value and potential of these 14 branded products will be fully explored and unleashed and continually benefiting more patients.”   Hasten SVP, Head of Commercial Excellence, Hanson Zheng said:“Special thanks to each member of the teams on both sides for their tireless efforts and contributions in making this transaction possible. This acquisition is not only a major breakthrough in the Hasten's business development, but also a big step for Hasten to achieve the strategic goal of 'whole industry chain' and 'globalization'.”   Hasten VP, Head of Asia-Pacific, Peggy Fung said, “Hasten has always adhered to the principle of ‘rooted in China, thinking globally’. Relying on the existing long-term and stable Asia-Pacific business foundation built by the Celltrion team, Hasten will be able to make smooth transition and embrace rapid development soon. By synergizing the resources and advantages, we’ll expand to other markets and widen our business boundaries globally.”  #PanAsia #Hasten #Globalization #Healthcare #Keyofsuccess #innovative

📣 📣 We are very pleased to announce that, Peggy Fung joins Hasten Biopharmaceutical Company Limited as our Vice President, Head of Asia-Pacific. Peggy Fung had over 28 years of pharmaceutical industry experience as a seasoned business leader with proven success in China, Hong Kong, India, Malaysia and APAC region. Prior to joining Hasten, Peggy was Vice President, Head of China Vaccine of GSK to manage inline Vx products and future portfolio prioritization. She also held various key positions as Hong Kong General Manager under Greater China and Intercontinental region in GSK, Country Manager in Pfizer Malaysia & Brunei, the Senior Director of Marketing in Pfizer India, Regional Therapeutic Area Lead for Anti-infectives and Critical Care Business in Emerging Asia and etc. During these years, Peggy has gained extensive experience and insights in sales & marketing, P&L management with strong financial and business acumen in various countries of the Asia Pacific region. Please join us in welcoming Peggy Fung to Hasten! We believe that with Peggy in the management team, we will achieve a strong business performance in the Asia Pacific region, as well as benefiting more patients during our journey of globalization.   #globalization #PanAsia

New era begins!

📢 BREAKING NEWS 📢 Hasten Announces Acquisition of 14 Celltrion Legacy Products, Accelerating its Business Expansion in the Pan-Asia Area. Hasten Biopharmaceutical Co., Ltd. (Hasten) announced today that it has successfully acquired the asset rights of 14 branded products across Pan-Asia countries and regions from Celltrion, a Korean biopharmaceutical company. According to the agreement, Hasten will also own the Marketing Authorization Holder (MAH) rights for these products in 8 countries and regions, including South Korea(Excluding Nesina®, Edarbi® and Actos®), Singapore, Thailand, Australia, China Hong Kong S.A.R.. The deal will enrich Hasten's product pipeline across 8 countries and regions outside mainland China, combined with more qualified global supply chain and a quality management system, which will surely pave the way for access to more high-quality products in the Pan-Asia Area. "This acquisition is strategically important to Hasten's continued growth and we're delighted to be part of the company's expansion journey." Fu Wei, CEO of CBC Group stated, "Driven by the dual forces of 'Hasten Speed' and 'Hasten Power', the company is well-positioned to tap into more potentials and benefit more patients. Moving forward, we will continue to leverage our unique 'Investor-Operator' approach to support Hasten in making a collective impact. By joining forces, we aim to build a health ecosystem spanning the Pan-Asia region and beyond, providing high-quality treatments and services to more patients, contributing to the development of the global healthcare industry." Summer XIA Shaofei, CEO of Hasten, said, "This acquisition marks a significant step in Hasten's business expansion in Pan-Asia and serves as an important milestone of our globalization trajectory. By expanding a commercial layout spanning multiple regions in Pan-Asia and covering more classic products, we have broadened Hasten's product portfolio while paving the ways for more high-quality products accessing Pan-Asia. This aligns with Hasten's development strategy of 'Pursuing Steady Progress'. We will continue to make full use of our commercialization capability and innovative business models to serve patients in Pan-Asia and even globally with quality products and solutions, so as to create the social health value." https://lnkd.in/gvarVMWz #Hasten #PanAsia #Healthcare #goingoverseas #globalization

📢 📢 On May. 17th, 2024, Hasten Biopharmaceutical Co., Ltd. (hereinafter as Hasten) announced that the clinical trial application (IND) for Lerodalcibep(hereinafter as the code：HST101), a novel third-generation PCSK9 inhibitor, has been approved by the Center for Drug Evaluation(CDE) of the National Medical Products Administration (NMPA) for the treatment of patients with hypercholesterolemia. The Company will accelerate domestic clinical trial preparations and initiate recruitment of subjects with hypercholesterolaemia. Summer XIA Shaofei, CEO of Hasten, said：“We are very pleased that HST101 clinical trial application has received the approval from the CDE of NMPA, which not only marks the birth of Hasten’s first IND approval, but also means that our first product under development has officially entered the clinical development stage in China. This also further manifests that Hasten’s pipeline development capability is becoming more mature, which will surely assist our R&D progress dashing forward with an ‘accelerated pace’. ” Dr. Shen Xiao, MD., Ph.D., CMO of Hasten, said: “Based on our partner LIB Therapeutics' overseas clinical trial data, HST101 has manifested convincing clinical efficacy and patient-friendly characters. We are looking forward to the clinical performance among Chinese patients during the IND. Hasten will accelerate the clinical development pace of HST101 at full speed to provide an innovative and efficient treatment for patients suffering from hypercholesterolaemia.” The IND application approved by CDE includes two clinical trials, Phase 1 and Phase 3, which will be mainly managed by #Hasten to conduct trials covering pharmacokinetic, pharmacodynamic, and efficacy and safety evaluations among Chinese healthy study participants (Phase 1) and patients with hypercholesterolaemia including heterozygous familial hypercholesterolaemia (HeFH) (Phase 3) respectively. Following the completion and positive results of the HST101 global Phase 3 overseas clinical trial project, the two upcoming registrational clinical trials in Chinese patients are expected to support the faster approval of Lerodalcibep, providing healthcare professionals and patients with new therapeutic choices, as well as helping more hyperlipidaemia patients to achieve LDL-C targets as early as possible. #Lerodalcibep #PCSK9 #HST101 #LDL-C #clinicaltrial #NMPA #Innovationdrugs